Investigational Drug Information for TD-4208
✉ Email this page to a colleague
What is the drug development status for TD-4208?
TD-4208 is an investigational drug.
There have been 13 clinical trials for TD-4208.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Lung Diseases, Obstructive, Lung Diseases, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are Theravance Biopharma, Mylan Inc., and Theravance Biopharma R & D, Inc.
There are forty-nine US patents protecting this investigational drug and two hundred and thirty-nine international patents.
Summary for TD-4208
| US Patents | 49 |
| International Patents | 239 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 39 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2015-09-01) |
| Vendors | 38 |
Recent Clinical Trials for TD-4208
| Title | Sponsor | Phase |
|---|---|---|
| A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD | Mylan Inc. | Phase 3 |
| A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD | Theravance Biopharma | Phase 3 |
| Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD | Theravance Biopharma | Phase 3 |
Clinical Trial Summary for TD-4208
Top disease conditions for TD-4208
Top clinical trial sponsors for TD-4208
US Patents for TD-4208
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TD-4208 | See Plans and Pricing | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| TD-4208 | See Plans and Pricing | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TD-4208
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TD-4208 | Australia | AU2010273514 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | Brazil | BR112012000890 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | Canada | CA2765621 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | Canada | CA2989129 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | China | CN102470130 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | Cyprus | CY1117075 | 2029-07-15 | See Plans and Pricing |
| TD-4208 | Denmark | DK2453894 | 2029-07-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
